Direct oral anticoagulants (DOACs): From the laboratory point of view
Direct oral anticoagulants (DOACs) represent a new generation of drugs that have been increasingly used in the prevention and treatment of thromboembolic states. According to the mechanism of anticoagulant action, DOACs are divided into two groups: direct inhibitors of thrombin (dabigatran) and dire...
Saved in:
Main Authors: | Margetić Sandra, Goreta Sandra Šupraha, Ćelap Ivana, Razum Marija |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2022-12-01
|
Series: | Acta Pharmaceutica |
Subjects: | |
Online Access: | https://doi.org/10.2478/acph-2022-0034 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Balancing the risks: continuous vs. interrupted anticoagulation during TAVI – what does the evidence say?
by: Ravi Patel, et al.
Published: (2025-01-01) -
Direct oral anticoagulants for stroke prevention and risk of bleeding
by: Tomoyuki Kawada
Published: (2025-02-01) -
Influence of novel oral anticoagulants on anticoagulation care management
by: Janzic Andrej, et al.
Published: (2017-09-01) -
Prothrombin complex concentrate for reversal of oral anticoagulants in patients with oral anticoagulation-related critical bleeding: a systematic review of randomised clinical trials
by: Christian Ovesen, et al.
Published: (2025-02-01) -
Direct-Acting Oral Anticoagulants in the Management of Cerebral Venous Sinus Thrombosis—Where Do We Stand?
by: Nikhil Vojjala, et al.
Published: (2025-01-01)